Food and Drug Administration on the use of the drug has been approved proved to be the effects of slow degraded rare diseases.
This is the first time in more than two decades in which the agency has agreed to treat amyotrophic sclerosis the adhesive disease that is also known as Lou Gehrig's disease, which affects 12,000-15,000 people in the United States.
On Friday, it was given FDA approval for the drug Mitsubishi Tanabe Pharma America Radriqava or Adaravon. It is expected to be available in August / August.
The FDA said the approval came after a Japanese study showed the benefits of the drug.
And they tested the experiment, which lasted six months, over 100 people, and found that those who used Aydaravon "Ankhvadwa" in terms of day-to-day work in front of non-drug users.
Dr. Eric Bastngs, deputy director of Product Division of Neurology at the Drug Evaluation Center and Medicine Authority, according to the agency was quick to encourage drug manufacturers to provide medicine to make it available in the U.S.
Bastngs said "This is the first new FDA approved treatment for Alicia in the country for many years," and we are happy that people with ALS will now have an additional option. "
Previously, it was the only drug approved by the FDA to treat ALS Rilutik, according to the Mayo Clinic. Rilutk or Relozul, was granted FDA approval in 1995.
Read more: Als is slowly stealing former singer Tim Shaw from his muscles. But he will not let it stop him from living.
Als kills neurons related to voluntary muscles. The disease, which is getting worse over time, can prevent vital movements, such as chewing, breathing, talking and walking. The muscles of the FDA over time become weak and usually the person dies because of respiratory failure with 3-5 years.
Radriqava will be given by infusion for two weeks to begin, followed by a 14-day drug-free period. Then they follow the courses for periods of two weeks, followed by periods without medication.
Radriqava side effects. The FDA said participants in the trial faced bruises and walking problems. It can also cause hives, swelling, shortness of breath and allergic diseases.
ALS Association claims Radriqava "is not a cure" but it can help people living with the disease. He said the price goes to Radriqava $ 11,000 for each dose cycle, or about $ 146,000 per year.
However, it was Pharma America said it will provide the medicine at no cost to those who are uninsured and who have certain Albion requirements.
No comments:
Post a Comment